Patient Safety & Systems-Based Practice

Hand hygiene and healthcare-associated infection prevention

Clinical Overview and When to Suspect Healthcare-Associated Infection

— CLABSI (central line-associated bloodstream infection)

— CAUTI (catheter-associated UTI)

— VAP/HAP (ventilator-associated and hospital-acquired pneumonia)

— SSI (surgical site infection)

— CDI (C. difficile infection)

— Fever, leukocytosis, or hemodynamic change appears >48h after admission

— New confusion or functional decline in an elderly inpatient (often the only sign of CAUTI or bacteremia)

— Worsening after initial improvement post-op or post-procedure

— Diarrhea ≥3 unformed stools/24h in a patient who received antibiotics within 90 days → CDI

— New infiltrate + purulent secretions + worsening oxygenation ≥48h after intubation → VAP

— Compliance averages only 40–60% in US hospitals despite being free and well-studied

Board pearl: On Step 3, any inpatient who develops a new fever, mental status change, or hypotension >48h after admission should trigger an HAI workup — and the prevention answer almost always centers on hand hygiene, device removal, and bundle adherence, not a new antibiotic. The cheapest, highest-yield intervention on the exam is always soap or alcohol-based hand rub.

Healthcare-associated infections (HAIs) are infections acquired ≥48 hours after admission, within 30 days of a procedure, or in association with healthcare delivery (dialysis, infusion centers, nursing homes)

Affect ~1 in 31 hospitalized US patients on any given day; ~99,000 deaths/year; major driver of CMS value-based purchasing penalties

The "Big 5" HAIs tracked by CMS/NHSN:

Suspect an HAI when:

Hand hygiene is the single most effective intervention to prevent HAIs — Semmelweis 1847; reaffirmed by WHO and CDC

Risk factors for HAI: indwelling devices (lines, Foleys, ETT), recent antibiotics, immunosuppression, prolonged LOS, ICU admission, age >65, prior colonization (MRSA, VRE, CRE)

Presentation Patterns and Key History

— Fever ± rigors temporally linked to line flushing or infusion

— Erythema, purulence, or tenderness at exit site (only ~30% of cases)

— Persistent bacteremia despite appropriate antibiotics → think line as source

— Common organisms: coagulase-negative staph, S. aureus, Enterococcus, Candida, gram-negatives

— Fever, suprapubic/flank pain, or new delirium in elderly with indwelling Foley

— Asymptomatic bacteriuria should NOT be treated except in pregnancy or pre-urologic procedure

— New/progressive infiltrate + ≥2 of: fever, leukocytosis, purulent secretions, hypoxemia

— Onset ≥48h after intubation (VAP) or ≥48h after admission (HAP)

— Superficial (≤30 days post-op): erythema, drainage, dehiscence

— Deep/organ-space (≤30 days, or ≤90 days with implant): fever, abscess, sepsis

— Watery diarrhea ≥3 stools/24h, abdominal pain, leukocytosis (sometimes >15,000 even before diarrhea)

— Recent antibiotic exposure (clindamycin, fluoroquinolones, cephalosporins, carbapenems most associated)

— PPI use is an independent risk factor

— Days since admission, surgery, intubation, or line placement

— Recent antibiotic course (agent, duration, completion date)

— Roommate or unit outbreak exposure

— Prior colonization (MRSA nares, VRE, ESBL, CRE)

— Healthcare exposure in past 90 days (dialysis, SNF, recent hospitalization)

Key distinction: Community-acquired infection presents at admission with prior symptoms; healthcare-associated infection emerges in the hospital trajectory and points to a device, procedure, or transmission event — the stem will always plant the timing clue (e.g., "POD#5," "intubated 4 days ago").

HAIs rarely present with textbook syndromes — Step 3 stems emphasize subtle inpatient deterioration and device-associated clues

CLABSI presentation:

CAUTI presentation:

VAP/HAP presentation:

SSI presentation:

CDI presentation:

Key history elements to extract from the stem:

Physical Exam Findings and Hemodynamic Assessment

— Temperature >38.0°C or <36.0°C; hypothermia in elderly/immunosuppressed is ominous

— qSOFA ≥2 (RR ≥22, SBP ≤100, altered mentation) → high mortality risk, escalate

— MAP <65 after 30 mL/kg crystalloid = septic shock, start vasopressors

— Lactate >2 mmol/L indicates tissue hypoperfusion; >4 confers very high mortality

— Inspect every CVC/PICC exit site: erythema, induration, purulence, tunnel tenderness

— Palpate along catheter tract for suppurative thrombophlebitis

— Examine Foley for sediment, encrustation, kinks, dependent drainage

— Inspect ETT cuff pressure, secretions, head-of-bed elevation

— Five cardinal signs: erythema, warmth, induration, drainage, dehiscence

— Crepitus or pain out of proportion → necrotizing fasciitis, surgical emergency

— Probe-to-bone test positive → osteomyelitis until proven otherwise

— Rhonchi, decreased breath sounds, increased ventilator pressures, purulent ETT suctioning

— Distension, tenderness, decreased bowel sounds → concern for toxic megacolon or ileus

— Absence of diarrhea in a sick patient does NOT rule out CDI if ileus is present

Step 3 management: A febrile ICU patient with a CVC in place ≥5 days should have the exit site examined and two sets of blood cultures drawn — one peripheral, one through the line — before any antibiotics. Differential time-to-positivity ≥2 hours (line positive earlier than peripheral) supports CLABSI and mandates line removal in most cases.

Exam in suspected HAI is device-focused and systems-focused — the answer is often "examine the line/Foley/wound," not "order more labs"

Vital signs and hemodynamic assessment:

Line and device exam (always do this):

Wound and surgical site exam:

Pulmonary exam in suspected VAP/HAP:

Abdominal exam in CDI:

Diagnostic Workup — Initial Labs, Imaging, and Cultures

— CBC with differential (leukocytosis, bandemia, or leukopenia)

— CMP (AKI, transaminitis suggest sepsis end-organ involvement)

— Lactate (repeat in 2–4h if elevated)

— Procalcitonin: useful for antibiotic de-escalation in LRTI/sepsis, NOT for HAI diagnosis

— Coags + DIC panel if septic shock

— Two sets of blood cultures from separate sites; if CVC present, one peripheral + one from the line

— Urine culture only if symptomatic — pyuria alone in catheterized patient is not diagnostic

— Sputum or endotracheal aspirate for VAP/HAP (≥10⁵ CFU/mL endotracheal, ≥10⁴ BAL)

— Wound cultures from deep tissue, NOT superficial swabs (skin flora contaminate)

— Stool NAAT or GDH + toxin EIA for CDI; do not test formed stool or "test of cure"

— CXR for suspected VAP/HAP/pneumonia — look for new or progressive infiltrate

— CT abdomen/pelvis for suspected intra-abdominal abscess, complicated CDI (megacolon), or post-op collection

— Ultrasound for line-associated DVT or suppurative thrombophlebitis

— Echo (TTE → TEE) for S. aureus bacteremia, persistent bacteremia, or prosthetic valve

— CLABSI: paired cultures + differential time-to-positivity

— CAUTI: replace catheter before culture if in place >2 weeks (avoids biofilm artifact)

— CDI: two-step algorithm (GDH/NAAT screen → toxin confirm)

— SSI: open wound, Gram stain, deep culture, imaging if deep/organ-space

Board pearl: Asymptomatic bacteriuria in a catheterized patient — even with pyuria and >10⁵ CFU/mL — is NOT treated except in (1) pregnancy or (2) prior to urologic procedure with mucosal trauma. Treating it drives resistance, C. difficile, and is a classic Step 3 trap distractor.

Initial labs for any suspected HAI:

Cultures BEFORE antibiotics (unless delay >45 min):

Imaging:

Bundle-aligned diagnostics by HAI type:

Diagnostic Workup — Advanced and Confirmatory Studies

— TTE within 5–7 days for all S. aureus bacteremia; TEE if TTE negative but suspicion high, prosthetic valve, persistent bacteremia >72h, or new murmur

— Repeat blood cultures every 48–72h until clearance documented

— Catheter tip culture (semiquantitative roll-plate, ≥15 CFU) only if line removed for suspected infection

— Bronchoscopic BAL or protected specimen brush for definitive microbiology in immunocompromised or non-responding patients

— Galactomannan/β-D-glucan if invasive fungal concern

— Legionella urinary antigen and respiratory viral PCR (influenza, RSV, SARS-CoV-2)

— Abdominal CT if severe/fulminant: bowel wall thickening, "accordion sign," ascites, megacolon (colon >6 cm)

— Lactate, albumin <2.5, WBC >25,000, or Cr >1.5× baseline define fulminant CDI → surgical consult

— MRI for osteomyelitis, deep abscess, or implant infection

— ESR/CRP trends for orthopedic hardware infection

— Sinus tract or fistula imaging with contrast

— NHSN reporting is mandatory for CMS-participating hospitals

— Molecular typing (PFGE, whole-genome sequencing) for cluster identification

— Active surveillance cultures (MRSA nares, VRE rectal) per institutional protocol

— Always obtain MIC for S. aureus (vancomycin MIC >2 → consider alternative)

— ESBL, AmpC, CRE phenotypes guide carbapenem vs novel β-lactam choice

Key distinction: A positive catheter tip culture without bacteremia does NOT diagnose CLABSI — it reflects colonization. CLABSI requires a recognized pathogen in ≥1 blood culture AND the organism is not related to another infection site. This nuance shows up on infection control questions and CMS-reporting stems.

When initial workup is inconclusive or HAI is complicated:

CLABSI advanced studies:

VAP/HAP advanced studies:

CDI advanced studies:

SSI advanced studies:

Surveillance and outbreak investigation:

Antimicrobial susceptibility:

Risk Stratification and Prevention Bundle Logic

— 1) Before patient contact

— 2) Before aseptic task

— 3) After body fluid exposure risk

— 4) After patient contact

— 5) After contact with patient surroundings

— Soap and water required for: visibly soiled hands, C. difficile exposure (spores resist alcohol), norovirus, Bacillus anthracis

— Hand hygiene + maximal sterile barrier precautions at insertion

— Chlorhexidine skin antisepsis (>0.5% with alcohol)

— Avoid femoral site in adults

— Daily review of line necessity; remove when not needed

— Chlorhexidine bathing in ICU

— Insert only for appropriate indications (NOT for incontinence or convenience)

— Aseptic insertion, closed drainage, dependent drainage

— Daily necessity review; nurse-driven removal protocols

— Head of bed 30–45°

— Daily sedation interruption and spontaneous breathing trials

— Oral care with chlorhexidine (controversial in non-cardiac surgery)

— DVT and stress ulcer prophylaxis

— Subglottic suctioning ETT for anticipated intubation >48h

— Appropriate preop antibiotic within 60 min of incision (120 min for vanco/fluoroquinolones)

— Normothermia, normoglycemia (<180 mg/dL), chlorhexidine-alcohol skin prep

— Clipping (not shaving) hair if removal needed

Step 3 management: When a question stem describes a CLABSI rate increase on a unit, the first intervention is observed audits of hand hygiene compliance and bundle adherence — not new antibiotic protocols or line product changes.

Step 3 emphasizes prevention bundles over treatment — the "best next step" in a prevention stem is almost always a bundle element, with hand hygiene as the foundation

WHO "5 Moments for Hand Hygiene":

Alcohol-based hand rub (ABHR) preferred for most encounters (faster, better compliance, less skin damage)

CLABSI prevention bundle:

CAUTI prevention bundle:

VAP prevention bundle:

SSI prevention:

Pharmacotherapy — Empiric Antibiotic Selection for HAIs

— Vancomycin (covers MRSA, coag-neg staph) PLUS

— Antipseudomonal β-lactam (cefepime, piperacillin-tazobactam, or meropenem) for gram-negative coverage

— Add echinocandin (micafungin) if: TPN, prolonged broad-spectrum antibiotics, femoral catheter, Candida colonization at multiple sites, or septic shock

— Ceftriaxone if low MDRO risk

— Piperacillin-tazobactam or cefepime if prior resistant organisms or critical illness

— Carbapenem if known ESBL colonization

— Narrow promptly based on urine culture; treat 7 days if rapid response, 10–14 days if delayed

— MRSA coverage (vancomycin or linezolid) if: prior IV antibiotics in 90 days, septic shock, MRSA prevalence >20% locally

— Two antipseudomonal agents from different classes if structural lung disease, prior resistant Pseudomonas, or septic shock

— Otherwise single antipseudomonal β-lactam acceptable

— Duration: 7 days for most VAP/HAP (extended only for non-fermenters with poor response)

— Initial episode (non-severe or severe): fidaxomicin 200 mg PO BID × 10 days (preferred) or vancomycin 125 mg PO QID × 10 days

— Fulminant (hypotension, ileus, megacolon): vancomycin 500 mg PO/NG QID + IV metronidazole 500 mg q8h; surgical consult

— First recurrence: fidaxomicin or pulsed/tapered vancomycin

— Multiple recurrences: consider bezlotoxumab adjunct or fecal microbiota transplant

Board pearl: When a stem describes CDI plus ileus/no diarrhea, you must add IV metronidazole because oral vancomycin won't reach the colon — and you must never give IV vancomycin for CDI (it's not excreted into the gut lumen). This is among the highest-yield CDI traps on Step 3.

Empiric therapy for HAI assumes multidrug-resistant organism (MDRO) risk until cultures return

CLABSI empiric:

CAUTI empiric (symptomatic, systemic illness):

HAP/VAP empiric (IDSA/ATS 2016):

CDI treatment (IDSA 2021):

Metronidazole is NO longer first-line for CDI in adults

Source Control, Device Management, and Procedural Decisions

— Remove the line immediately for: S. aureus, P. aeruginosa, Candida, mycobacteria, persistent bacteremia >72h, septic shock, tunnel/pocket infection, suppurative thrombophlebitis, endocarditis

— May attempt salvage with antibiotic lock therapy for coag-neg staph or enterococcus in limited-access patients

— Reinsert new line at a different site after 48–72h of clearance documented

— Replace or remove the Foley before initiating antibiotics if in place >2 weeks

— Switch to condom catheter, intermittent catheterization, or bedside commode whenever possible

— Open and drain superficial wounds; pack and reassess

— Surgical washout for deep/organ-space SSI

— Hardware retention possible if early (<3 weeks), stable implant, susceptible organism (not MRSA/MRSE with biofilm); otherwise removal/exchange

— Percutaneous drainage (IR) for accessible collections ≥3 cm

— Surgical drainage if multiloculated, anatomically inaccessible, or failed percutaneous

— Megacolon, perforation, refractory shock, worsening despite 48h medical therapy

— Procedure: subtotal colectomy with end ileostomy OR diverting loop ileostomy with colonic lavage (lower mortality)

— Tube thoracostomy for parapneumonic effusion with pH <7.2, glucose <40, or positive Gram stain

— VATS or decortication for organized empyema

CCS pearl: On a CCS case of CLABSI with S. aureus bacteremia, your high-impact orders are: (1) remove the central line, (2) draw repeat blood cultures q48h until negative, (3) start vancomycin, (4) order TTE (TEE if negative or prosthetic valve), and (5) ID consult. Forgetting line removal will sink the case.

Source control is co-equal with antibiotics — Step 3 stems frequently test the timing and indication for device removal or procedural intervention

CLABSI line management:

CAUTI catheter management:

SSI source control:

Intra-abdominal abscess:

CDI surgical indications (fulminant):

Empyema/VAP complications:

Special Populations — Elderly and Renal/Hepatic Impairment

— Delirium or functional decline may be the only sign of CAUTI, CLABSI, or pneumonia

— Blunted fever response; hypothermia may signal severe sepsis

— Polypharmacy increases CDI risk (especially PPIs, anticholinergics, opioids)

— Higher baseline MDRO colonization from SNF/LTACH exposure

— Vancomycin: target AUC 400–600 mg·h/L (preferred over trough monitoring); reduce frequency in CKD; consider linezolid or daptomycin if AKI

— Piperacillin-tazobactam: renal adjustment required; avoid concurrent vancomycin in CKD/AKI when possible (vanc-pip-tazo synergistic nephrotoxicity)

— Aminoglycosides: extended-interval dosing with levels; avoid if eGFR <30

— Cefepime: reduce dose to avoid neurotoxicity/encephalopathy in CKD

— Fluconazole, fluoroquinolones: require renal adjustment

— Tigecycline, ceftriaxone, metronidazole: caution in severe hepatic disease

— Avoid rifaximin dose changes; safe in cirrhosis but watch for resistance

— Linezolid: monitor for lactic acidosis (mitochondrial toxicity), thrombocytopenia >14 days

— Higher mortality; lower threshold for fidaxomicin (lower recurrence)

— Strongly consider bezlotoxumab in patients ≥65 with prior CDI episode

— Up to 50% of nursing home residents have ASB; treating it causes harm

— Even with delirium, look for another source first; treat only if no alternative explanation AND localizing urinary signs

Step 3 management: An elderly nursing-home resident admitted with delirium, indwelling Foley, and pyuria should have the catheter removed (or replaced), a broad sepsis workup, and antibiotics only if there are systemic signs or an alternative source is excluded — empiric treatment of bacteriuria alone is the wrong answer.

Elderly patients are disproportionately affected by HAIs and present atypically

Renal impairment dosing:

Hepatic impairment:

CDI in elderly:

Asymptomatic bacteriuria pitfall:

Special Populations — Pregnancy, Pediatrics, Immunocompromised, and Dialysis

— Asymptomatic bacteriuria MUST be treated in pregnancy (prevents pyelonephritis, preterm labor); screen at 12–16 weeks

— Preferred: nitrofurantoin (avoid near term and in G6PD), cephalexin, fosfomycin

— Avoid fluoroquinolones, tetracyclines, TMP-SMX (1st trimester and near term)

— HAI prevention: same bundles; hand hygiene unchanged

— CLABSI rates highest in NICU; chlorhexidine bathing benefit less clear <2 months

— CAUTI uncommon; suprapubic catheter or intermittent cath preferred for prolonged drainage

— CDI testing only if ≥1 year (high carriage in infants); treat symptomatic disease only

— Lower fever threshold (single temp ≥38.3°C or ≥38.0°C sustained 1h) triggers full sepsis workup

— Empiric cefepime, pip-tazo, or meropenem monotherapy for febrile neutropenia

— Add vancomycin for: catheter infection, skin/soft tissue, mucositis, hemodynamic instability, MRSA colonization

— Antifungal coverage if fever persists ≥4–7 days despite broad-spectrum antibiotics

— Tunneled catheters confer highest CLABSI risk; AV fistula > AV graft > catheter

— S. aureus nasal decolonization with mupirocin reduces bacteremia

— Vancomycin dosed by levels, given during/after dialysis sessions

— Aspergillus risk in immunocompromised → HEPA filtration, barriers, ICRA assessment

Board pearl: Asymptomatic bacteriuria in pregnancy and prior to urologic procedures with mucosal trauma are the only two scenarios where treating ASB is correct. Memorize this — it appears in nearly every Step 3 patient safety/antimicrobial stewardship block.

Pregnancy:

Pediatrics:

Immunocompromised (neutropenic, transplant, chemo):

Hemodialysis patients:

Hospital construction/renovation:

Complications and Adverse Outcomes

— Mortality 30–50% in HAI-associated septic shock

— Each hour of delayed appropriate antibiotics increases mortality ~7%

— AKI, ARDS, DIC, ischemic hepatitis common

— Infective endocarditis (especially S. aureus, Enterococcus, Candida)

— Septic pulmonary emboli from right-sided endocarditis or suppurative thrombophlebitis

— Metastatic abscess (epidural, vertebral osteomyelitis, splenic)

— Persistent bacteremia → mandates source re-evaluation and TEE

— Pyelonephritis, renal abscess, urosepsis

— Catheter encrustation and bladder calculi with chronic indwelling

— Empyema, lung abscess, prolonged ventilation, tracheostomy dependence

— ARDS, ventilator-induced lung injury

— Toxic megacolon, perforation, fulminant colitis — mortality up to 50% in fulminant

— Recurrence: 20–25% after first episode; 40–60% after subsequent

— Post-infectious IBS; rare reactive arthritis

— C. difficile induction from unnecessary antibiotics

— AKI (vanc + pip-tazo, aminoglycosides, contrast)

— Vanc-induced DRESS, red man syndrome (infusion rate, not allergy)

— Linezolid: serotonin syndrome with SSRIs, thrombocytopenia, lactic acidosis

— Selection for MDROs: ESBL, CRE, VRE, MDR-Pseudomonas, Candida auris

— Prolonged LOS (average +5–20 days), readmissions, ICU transfer

— CMS HAC penalty: 1% Medicare payment reduction for worst-performing hospitals

Key distinction: Recurrent CDI within 8 weeks of initial episode = recurrence (same strain, treat with fidaxomicin or pulsed vanco ± bezlotoxumab). New episode after 8 weeks = reinfection (treat as new episode). This distinction guides regimen choice and risk-stratifies for FMT referral.

Septic shock and multiorgan failure:

CLABSI-specific complications:

CAUTI complications:

VAP complications:

CDI complications:

Antimicrobial-related adverse outcomes:

Patient and system-level harm:

When to Escalate Care — ICU, Consults, and Transfers

— Septic shock requiring vasopressors after fluid resuscitation

— Respiratory failure requiring mechanical ventilation or high-flow >40 L/min

— Lactate >4 mmol/L or not clearing with resuscitation

— Altered mental status, qSOFA ≥2 with worsening trajectory

— DIC, severe AKI requiring CRRT

— S. aureus bacteremia (improves mortality, ensures appropriate duration and TEE)

— Candida bloodstream infection

— MDRO infections (CRE, MDR-Pseudomonas, C. auris)

— Suspected endocarditis, osteomyelitis, prosthetic device infection

— Recurrent or fulminant CDI

— OPAT planning at discharge

— Necrotizing soft tissue infection (emergent debridement)

— Deep or organ-space SSI requiring washout

— Fulminant CDI with megacolon, perforation, or refractory shock

— Drainable abscess not amenable to IR

— Percutaneous drainage of intra-abdominal, pelvic, or hepatic abscess

— Tunneled line removal if surgically complex

— Outbreak clusters (≥2 cases of same MDRO in time/place)

— C. auris, novel resistance mechanisms

— Construction-associated Aspergillus or Legionella

— Mandatory NHSN reporting and public reporting concerns

— De-escalation at 48–72h based on cultures

— Duration optimization (most HAIs: 7 days unless complicated)

CCS pearl: On any CCS case with persistent S. aureus bacteremia despite 48–72h of vancomycin, your sequence is: repeat blood cultures, order TEE, ID consult, evaluate for metastatic foci (MRI spine if back pain, CT for abscess), and ensure source control (line removal, drainage). Failure to order ID consult or TEE costs points.

ICU transfer criteria in suspected HAI/sepsis:

Infectious Diseases consultation indicated for:

Surgical consultation indicated for:

Interventional radiology:

Infection Preventionist / Hospital Epidemiology involvement:

Antimicrobial Stewardship Program:

Key Differentials — Other Infectious Sources in Hospitalized Patients

— Sinusitis in NG/NJ tube patients (fever of unknown source in ICU)

— Acalculous cholecystitis in critically ill, NPO, TPN-dependent patients

— Endocarditis (especially with prior bacteremia, prosthetic valve, IVDU history)

— Vertebral osteomyelitis/epidural abscess with back pain + bacteremia

— Septic arthritis in joint pain + fever

— Meningitis (post-neurosurgical, CSF leak, shunt)

— Transfusion-transmitted infection (rare but reportable)

— Transfusion-related sepsis (platelet contamination most common)

— Transplant donor-derived infection

— Influenza, RSV, SARS-CoV-2 outbreaks on units

— Norovirus on inpatient wards (alcohol rub ineffective → soap and water)

— Hepatitis B/C from needlestick or contaminated equipment (rare with modern sterilization)

— Candida (lines, TPN, broad-spectrum antibiotics)

— Aspergillus (construction, immunocompromised)

— Mucorales (DKA, immunocompromised)

— Pan-culture (blood ×2, urine, sputum, wound)

— CT chest/abdomen/pelvis

— Examine ALL devices and lines, including epidural catheters

— Echo if persistent bacteremia

— Stool studies if diarrhea

— Consider drug fever if no source after thorough workup (eosinophilia clue)

Board pearl: Drug fever is a diagnosis of exclusion but should be considered in any patient with persistent fever, no clear source, recent new medication (β-lactams, anticonvulsants, allopurinol, sulfa), relative bradycardia, and eosinophilia. Discontinuation produces defervescence within 72–96h.

When fever or sepsis emerges in a hospitalized patient, the differential extends beyond the "Big 5" HAIs

Other infectious sources to consider:

Donor- or product-related infections:

Healthcare-associated viral infections:

Fungal:

Workup approach when source unclear:

Key Differentials — Non-Infectious Causes of Fever in Inpatients

— Wind (atelectasis/pneumonia): POD 1–2; though atelectasis as fever cause is largely myth

— Water (UTI): POD 3–5

— Walking (DVT/PE): POD 4–6

— Wound (SSI): POD 5–7

— Wonder drugs (drug fever, transfusion reactions): any time

— DVT and PE commonly present with low-grade fever

— Especially after orthopedic surgery, prolonged immobility, malignancy

— Drug fever (β-lactams, phenytoin, allopurinol, sulfa)

— DRESS syndrome (fever, rash, eosinophilia, multiorgan)

— Neuroleptic malignant syndrome (antipsychotics)

— Serotonin syndrome (SSRI + linezolid, tramadol, MAOI)

— Malignant hyperthermia (volatile anesthetics, succinylcholine)

— Febrile non-hemolytic transfusion reaction

— Acute hemolytic transfusion reaction (ABO mismatch)

— TRALI, TACO

— Thyroid storm, adrenal insufficiency, pheochromocytoma

— Alcohol/benzodiazepine withdrawal

— Gout/pseudogout flare, postoperative

— Vasculitis, adult-onset Still's

— Pancreatitis, mesenteric ischemia

— Tumor fever (lymphoma, RCC, hepatocellular)

— Tumor lysis syndrome

Key distinction: Relative bradycardia (pulse-temperature dissociation) suggests drug fever, typhoid, Legionella, Brucella, or central fever — and argues against typical bacterial sepsis where tachycardia is expected. This sign should prompt review of the medication list before broadening antibiotics.

Not all inpatient fevers are infections — Step 3 frequently tests recognition of non-infectious mimics to avoid unnecessary antibiotics (which drive HAIs, especially CDI)

Postoperative fever — "5 Ws" mnemonic:

Venous thromboembolism:

Drug reactions:

Transfusion-related:

Endocrine/metabolic:

Inflammatory/autoimmune:

Malignancy:

Hematoma resorption or large bruise

Secondary Prevention, Discharge Planning, and Long-Term Strategy

— Confirm appropriate duration (most HAIs: 7 days; S. aureus bacteremia: ≥14 days uncomplicated, 4–6 weeks complicated)

— OPAT planning with weekly labs (CBC, CMP, drug level)

— Document indication, stop date, and follow-up plan

— Antimicrobial stewardship at transitions prevents downstream resistance and CDI

— MRSA nasal mupirocin + chlorhexidine bathing × 5 days for: pre-op cardiac/orthopedic surgery, recurrent MRSA SSTI, hemodialysis with prior MRSA bacteremia

— Universal ICU chlorhexidine bathing reduces CLABSI

— Influenza (annual, all inpatients in season)

— Pneumococcal (PCV15/20, PPSV23 per ACIP)

— COVID-19 boosters per current guidance

— Tdap, RSV per age and risk

— Avoid unnecessary antibiotics (highest recurrence risk)

— Counsel on prompt return for diarrhea

— Consider probiotics — evidence mixed, not routinely recommended

— FMT referral for ≥2 recurrences

— Re-evaluate need for long-term access; consider PICC vs port vs tunneled CVC

— Patient/caregiver education on line care, hand hygiene at home, signs of infection

— NHSN benchmarking and standardized infection ratio (SIR) tracking

— Unit-based safety huddles, daily line/Foley rounds

— Computerized order sets with hard stops for device necessity

Step 3 management: At discharge from a CLABSI hospitalization, the medication reconciliation must include a clearly documented antibiotic stop date and a scheduled OPAT lab follow-up (typically weekly CBC/CMP + drug levels). Missing this is a common transitions-of-care safety failure tested on Step 3.

HAI prevention extends beyond the acute episode into system-level secondary prevention and discharge transitions

Discharge antibiotic management:

Decolonization strategies (selected patients):

Vaccination at discharge (HAI-relevant):

Post-CDI patients:

Post-CLABSI/line patients:

System-level prevention:

Follow-Up, Monitoring, and Counseling

— Clinical response (defervescence, hemodynamic stability, end-organ recovery) at 48–72h

— Repeat blood cultures q48–72h for S. aureus/Candida bacteremia until clearance

— Procalcitonin trends may support de-escalation but should not solely drive duration

— Daily review of antimicrobial necessity and culture data

— Vancomycin: AUC-guided dosing preferred (target 400–600); trough 15–20 acceptable; SCr q2–3 days

— Aminoglycosides: peak/trough levels; daily SCr and audiology if >7 days

— Linezolid: weekly CBC (thrombocytopenia), watch for serotonin syndrome

— Daptomycin: weekly CK; do NOT use for pneumonia (inactivated by surfactant)

— Cefepime: mental status monitoring (encephalopathy in CKD)

— Primary care or hospital follow-up within 7–14 days

— OPAT clinic weekly while on IV therapy

— ID follow-up 2–4 weeks after completion for complicated infections

— Hand hygiene at home, especially before line/wound care

— Recognize warning signs: fever, redness/drainage, line pain, return of diarrhea

— Medication adherence, side effects, when to call

— Avoid unnecessary antibiotic requests (e.g., for viral URIs)

— Post-sepsis syndrome: cognitive impairment, depression, weakness lasting months

— PT/OT referral for deconditioning

— Mental health screening at follow-up

— Annual hand hygiene training and observed audits

— Feedback of unit-level HAI and compliance data

Board pearl: Post-sepsis syndrome (cognitive, physical, psychiatric sequelae) affects up to 50% of sepsis survivors. Step 3 stems may test recognition of new functional decline, depression, or PTSD at a post-discharge visit — the correct answer is comprehensive multidisciplinary follow-up, not a new infectious workup.

Monitoring during therapy:

Drug-specific monitoring:

Post-discharge follow-up cadence:

Patient counseling:

Rehabilitation considerations:

Healthcare worker counseling:

Ethical, Legal, and Patient Safety Considerations

— National Patient Safety Goal (Joint Commission NPSG.07.01.01)

— Failure constitutes a breach of standard of care and contributes to malpractice exposure

— "Just culture" framework: address system failures, not just individuals; punitive responses reduce reporting

— NHSN reporting of CLABSI, CAUTI, SSI (selected procedures), MRSA bacteremia, CDI is required for CMS-participating hospitals

— Public reporting on Hospital Compare; affects value-based purchasing

— Some states require additional reporting (e.g., C. auris often reportable to public health)

— Patients have the right to know HAI risks before line placement, surgery, or invasive procedures

— Hospital-acquired conditions (HACs): CMS does not reimburse hospitals for select HAIs deemed reasonably preventable

— Medication reconciliation must document antibiotic indication, duration, stop date

— Failure to communicate active infection or MDRO status to receiving facility is a sentinel event risk

— Use structured handoff tools (SBAR, I-PASS)

— When an HAI causes harm, ethical and (in many states) legal duty to disclose

— Apology laws in many states protect expressions of empathy

— Duty to perform hand hygiene; refusal of vaccination (e.g., influenza) may have institutional consequences

— Bloodborne pathogen exposure: OSHA-mandated post-exposure protocols

— Prescribing unnecessary antibiotics harms future patients via resistance — a population-level ethical concern

— Joint Commission requires ASP at all accredited hospitals

Step 3 management: A patient develops CLABSI with S. aureus bacteremia after a CVC was placed without documented chlorhexidine prep or maximal barriers. The correct next step includes disclosure to the patient and family, root-cause analysis, and reporting through the hospital's event reporting system — not silence or chart correction. Honest disclosure improves trust and may reduce litigation.

Hand hygiene as a patient safety culture marker:

Mandatory reporting:

Informed consent considerations:

Transitions of care safety:

Disclosure of harm:

Healthcare worker obligations:

Antimicrobial stewardship as ethics:

High-Yield Associations and Rapid-Fire Clinical Facts

— Semmelweis (1847) — handwashing reduced puerperal sepsis mortality from 18% to 2%

— ABHR >30% efficacy gain over soap and water for most pathogens (except spores, norovirus)

— Apply ABHR to dry hands; rub until dry (~20 sec)

— Soap and water: ≥20 sec, all surfaces, dry with disposable towel

— C. difficile spores: resist alcohol → soap and water + contact precautions with gown and gloves + bleach for environment

— Norovirus: alcohol partially effective → soap and water preferred

— Candida auris: resistant, hard to eradicate; chlorhexidine and bleach; private room

— VRE: contact precautions; environment is reservoir

— MRSA: contact precautions; nasal mupirocin + chlorhexidine for decolonization

— Standard — all patients

— Contact — MRSA, VRE, CDI, draining wounds, lice, scabies

— Droplet — influenza, pertussis, meningococcus, mumps

— Airborne — TB, measles, varicella, disseminated zoster (N95 + negative pressure)

— Pronovost Michigan keystone ICU project: CLABSI ↓66% with checklist

— Hand hygiene + CHG bathing: CLABSI ↓40–50% in ICU

— Highest risk: clindamycin, fluoroquinolones, 3rd/4th-gen cephalosporins, carbapenems

— Lower risk: doxycycline, macrolides, aminoglycosides

— CLABSI, CAUTI, certain SSIs, stage III/IV pressure ulcers, falls with injury

Board pearl: When a Step 3 stem mentions a patient with watery diarrhea after antibiotics, the next step in PPE is gown, gloves, and soap-and-water hand hygiene on exit — alcohol rub does not kill C. difficile spores. This single fact appears in nearly every infection control block.

Hand hygiene rapid facts:

Pathogen-specific quick facts:

Isolation precaution categories:

Bundles save lives — landmark data:

Antibiotic ↔ CDI association strength:

CMS Hospital-Acquired Conditions (selected non-reimbursed):

Board Question Stem Patterns

— Stem: ICU patient with CVC ×5 days, new fever, no other localizing signs

— Best initial step: two sets of blood cultures (one peripheral, one through line) + line site exam

— Best management if S. aureus grows: remove line, vancomycin, TTE/TEE, ID consult

— Stem: post-cholecystectomy patient on ceftriaxone develops 6 watery stools, WBC 18,000

— Best test: stool NAAT or GDH/toxin

— Best treatment: oral fidaxomicin or oral vancomycin; contact precautions, soap-and-water hand hygiene, dedicated equipment

— Stem: nursing home patient, indwelling Foley, urine culture 10⁵ E. coli, no fever, no symptoms

— Best step: no antibiotics; consider Foley removal/replacement

— Stem: rising CLABSI rate on unit, audit shows 45% hand hygiene compliance

— Best intervention: direct observation + feedback + multimodal strategy (education, reminders, accountability)

— Best next steps: repeat cultures, TEE, evaluate for metastatic foci, ID consult, source control

— Best answers: HOB 30–45°, daily sedation interruption, SBT, oral care, DVT/stress ulcer prophylaxis

— Best answers: antibiotic within 60 min of incision, clipping not shaving, normothermia, glucose <180, chlorhexidine-alcohol prep

— Stem: patient discharged on IV antibiotics, readmitted with no follow-up labs

— Best answer: structured OPAT program with weekly monitoring and ID follow-up

Step 3 management: When the stem features rising HAI rates or bundle non-compliance, the correct answer is almost never a new drug or technology — it is observation, feedback, and culture change rooted in hand hygiene and bundle adherence.

Pattern 1: Inpatient day 4 fever with CVC

Pattern 2: Post-op POD#5 with diarrhea on antibiotics

Pattern 3: Asymptomatic bacteriuria in elderly with Foley

Pattern 4: Hand hygiene compliance gap

Pattern 5: Persistent S. aureus bacteremia despite vancomycin

Pattern 6: VAP prevention bundle

Pattern 7: Pre-op SSI prevention

Pattern 8: Transitions-of-care failure

One-Line Recap

Hand hygiene — the single most effective, lowest-cost intervention in medicine — combined with device-removal discipline, bundle adherence, and antimicrobial stewardship, is the foundation of preventing the Big 5 healthcare-associated infections (CLABSI, CAUTI, VAP/HAP, SSI, CDI).

Board pearl: If a Step 3 stem asks for the most effective single intervention to reduce HAI rates on a unit, the answer is hand hygiene — every time, regardless of the specific pathogen or bundle in question.

Hand hygiene: ABHR for routine care; soap and water for C. difficile, norovirus, visibly soiled hands; WHO 5 Moments; observed audit + feedback is the highest-yield improvement strategy

Device discipline: every line, Foley, and ETT needs a daily necessity review — remove when not needed; this prevents more infection than any antibiotic

Empiric therapy: vancomycin + antipseudomonal β-lactam for most HAIs until cultures return; fidaxomicin or oral vancomycin for CDI (never IV vancomycin); add echinocandin for Candida risk; source control is co-equal with antibiotics

Do NOT treat asymptomatic bacteriuria except in pregnancy or before urologic procedures with mucosal trauma — this is the single most-tested antimicrobial stewardship pearl on Step 3

Transitions of care: document antibiotic stop dates, OPAT follow-up, MDRO status; honest disclosure of HAI harm aligns with ethics, patient safety culture, and modern malpractice prevention